Login
$RCT
$0.08 +$0.01 (8.67%) Close

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q4 FY2025
As of Dec 31, 2025
Q4 FY2024
As of Dec 31, 2024
ASSETS
Current Assets:
Cash and cash equivalents
Restricted Cash
Accounts receivables and other receivables, net
Income taxes receivable
Prepayments
Other current assets
Total Current Assets
Non Current Assets:
Property and equipment, net
Intangible assets, net
Investment in Joint Venture
Total Non Current Assets
Total Assets
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Accounts payable
Vouchers payable
Accrued expenses
Value-added tax payable
Other current liabilities
Shareholder loans payable
Short-term borrowings
Total Current Liabilities
Non Current Liabilities:
Convertible Shareholder loans, at fair value
Total Non current Liabilities
Total Liabilities
Common stock £0.002 par value; [79,420,315] shares authorized; 55,318,354 and 25,000,043 shares issued and outstanding as of December 31, 2025 and 2024, respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income
Total Stockholders’ Deficit
Total Liabilities and Stockholders’ Deficit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support